{"transactions":[{"id":916083,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T18:02:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":341900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":341900,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":341900},"source":{"system":"sec-edgar","filing":"0001781549-26-000013","document":"form4-02062026_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000013/form4-02062026_110255.xml","form_type":"4"}},{"id":916082,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T18:02:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":97700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":97700,"derivative":{"underlying":"Common Stock","underlying_shares":97700},"source":{"system":"sec-edgar","filing":"0001781549-26-000013","document":"form4-02062026_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000013/form4-02062026_110255.xml","form_type":"4"}},{"id":917778,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":20875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":62625,"derivative":{"underlying":"Common Stock","underlying_shares":20875},"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":917777,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":5937,"price":3.47,"value":20601.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":192260,"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":917776,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":20875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":198197,"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":917775,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":29500,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917774,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Resticted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917773,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917772,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":10686,"price":3.51,"value":37507.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":177322,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917771,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":188008,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917770,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":173258,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917769,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":165758,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":922012,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:34:33.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15980,"price":2.48,"value":39630.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported.  This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings."}],"balance_after":102773,"source":{"system":"sec-edgar","filing":"0001781549-26-000007","document":"form4-02032026_100229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000007/form4-02032026_100229.xml","form_type":"4"}},{"id":922011,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:32:06.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15980,"price":2.48,"value":39630.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported.  This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings."}],"balance_after":102773,"source":{"system":"sec-edgar","filing":"0001781549-26-000005","document":"form4a-02032026_100202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000005/form4a-02032026_100202.xml","form_type":"4/A","original_submission_date":"2025-02-04"}},{"id":951729,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":18150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":18700,"derivative":{"underlying":"Common Stock","underlying_shares":18150},"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951728,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951727,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":6171,"price":2.88,"value":17772.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":155041,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951726,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":18150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":161212,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951725,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":33994,"price":3.01,"value":102321.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":143062,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951724,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":177056,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":1285010,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":292300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such\ndate."}],"balance_after":292300,"derivative":{"exercise_price":2.4,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":292300},"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285009,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":83500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":83500,"derivative":{"underlying":"Common Stock","underlying_shares":83500},"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285008,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":44250,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285007,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Resticted Stock Units","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285006,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285005,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15447,"price":2.48,"value":38308.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":103306,"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285004,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":118753,"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285003,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":104003,"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1285002,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:08.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":96503,"source":{"system":"sec-edgar","filing":"0001415889-25-002938","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925002938/form4-02042025_040201.xml","form_type":"4"}},{"id":1315015,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:07.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":false,"shares":18150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":36850,"derivative":{"underlying":"Common Stock","underlying_shares":18150},"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315014,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:07.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":55000,"derivative":{"underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315013,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:07.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":73750,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315012,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:07.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8575,"price":2.48,"value":21266.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":85253,"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315011,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:07.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":true,"shares":18150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":93828,"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315010,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:07.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":32089,"price":2.48,"value":79580.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":75678,"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1315009,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:07.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":107767,"source":{"system":"sec-edgar","filing":"0001415889-25-000622","document":"form4-01032025_060104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000141588925000622/form4-01032025_060104.xml","form_type":"4"}},{"id":1659034,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":147500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":147500,"derivative":{"underlying":"Common Stock","underlying_shares":147500},"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659033,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":59000,"derivative":{"underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659032,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":206500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":206500,"derivative":{"exercise_price":1.2,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":206500},"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659031,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659030,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659029,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2568,"price":1.2,"value":3081.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":34017,"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659028,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":36585,"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659027,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3853,"price":1.2,"value":4623.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":29085,"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1659026,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:29:48.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":32938,"source":{"system":"sec-edgar","filing":"0001209191-24-002838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919124002838/doc4.xml","form_type":"4"}},{"id":1795409,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-28T16:39:24.000Z","date":"2023-08-28","kind":"purchase","planned":false,"acquired":true,"shares":14705,"price":6.7976,"value":99958.708,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.7699 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":21688,"source":{"system":"sec-edgar","filing":"0001209191-23-047522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123047522/doc4.xml","form_type":"4"}},{"id":2022831,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-10T16:55:20.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":4267,"price":13.8909,"value":59272.4703,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.80 to $13.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6983,"source":{"system":"sec-edgar","filing":"0001209191-23-008451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123008451/doc4.xml","form_type":"4"}},{"id":2033168,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T17:01:21.000Z","date":"2023-02-01","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":33750,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-23-006999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123006999/doc4.xml","form_type":"4"}},{"id":2033167,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T17:01:21.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-006999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123006999/doc4.xml","form_type":"4"}},{"id":2033166,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-03T17:01:21.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":105000,"derivative":{"exercise_price":16.97,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-23-006999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123006999/doc4.xml","form_type":"4"}},{"id":2033165,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-03T17:01:21.000Z","date":"2023-02-01","kind":"exercise","acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001209191-23-006999","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919123006999/doc4.xml","form_type":"4"}},{"id":2419406,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T16:50:26.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting\nPerson's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":45000,"derivative":{"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-22-005935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919122005935/doc4.xml","form_type":"4"}},{"id":2419405,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-01T16:50:26.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":155000,"derivative":{"exercise_price":11.58,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-22-005935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000120919122005935/doc4.xml","form_type":"4"}},{"id":2636488,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Restricted Stock Unit","published_at":"2021-07-12T20:15:29.000Z","date":"2021-07-08","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the second vesting installment of RSUs granted on July 8, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the second vesting installment of RSUs granted on July 8, 2019."}],"balance_after":3000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001171843-21-004833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321004833/ownership.xml","form_type":"4"}},{"id":2636487,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Common Stock","published_at":"2021-07-12T20:15:29.000Z","date":"2021-07-08","kind":"tax_withholding","acquired":false,"shares":731,"price":43.24,"value":31608.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":5592,"source":{"system":"sec-edgar","filing":"0001171843-21-004833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321004833/ownership.xml","form_type":"4"}},{"id":2636486,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Common Stock","published_at":"2021-07-12T20:15:29.000Z","date":"2021-07-08","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the second vesting installment of RSUs granted on July 8, 2019."}],"balance_after":6323,"source":{"system":"sec-edgar","filing":"0001171843-21-004833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321004833/ownership.xml","form_type":"4"}},{"id":2795535,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-11T22:14:27.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":16802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a 10% premium above the closing price of Anika's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The premium priced stock options vest in three equal annual installments beginning on March 9, 2022."}],"balance_after":16802,"derivative":{"exercise_price":37.4,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":16802},"source":{"system":"sec-edgar","filing":"0001171843-21-001712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001712/ownership.xml","form_type":"4"}},{"id":2795534,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Restricted Stock Unit","published_at":"2021-03-11T22:14:27.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":6705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."}],"balance_after":6705,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6705},"source":{"system":"sec-edgar","filing":"0001171843-21-001712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001712/ownership.xml","form_type":"4"}},{"id":2827869,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Restricted Stock Unit","published_at":"2021-03-01T22:19:56.000Z","date":"2021-02-25","kind":"exercise","acquired":false,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each DSU represents the contingent right to receive one share of the Company's common stock. The DSUs vest in three equal annual installments beginning on February 25, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each DSU represents the contingent right to receive one share of the Company's common stock. The DSUs vest in three equal annual installments beginning on February 25, 2021."}],"balance_after":3133,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0001171843-21-001429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001429/ownership.xml","form_type":"4"}},{"id":2827868,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Common Stock","published_at":"2021-03-01T22:19:56.000Z","date":"2021-02-25","kind":"exercise","acquired":true,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects the first vesting installment of deferred stock units (\"DSUs\") granted on February 25, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The settlement of these DSUs shall be deferred until the grantee incurs a \"separation of service\" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event."}],"balance_after":3323,"source":{"system":"sec-edgar","filing":"0001171843-21-001429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001429/ownership.xml","form_type":"4"}},{"id":3085240,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Common Stock","published_at":"2020-07-10T20:06:24.000Z","date":"2020-07-09","kind":"sale","acquired":false,"shares":1244,"price":35.15,"value":43726.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 1,244 shares of common stock sold by Mr. Loerop to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 9, 2020, Mr. Loerop sold 1,244 shares in one trade for $35.15."}],"balance_after":1756,"source":{"system":"sec-edgar","filing":"0001171843-20-004894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320004894/ownership.xml","form_type":"4"}},{"id":3085239,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Common Stock","published_at":"2020-07-10T20:06:24.000Z","date":"2020-07-08","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects the first vesting installment of RSUs granted on July 8, 2019."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001171843-20-004894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320004894/ownership.xml","form_type":"4"}},{"id":3244750,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Restricted Stock Unit","published_at":"2020-02-27T23:53:01.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a \"separation of service\" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a \"separation of service\" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event."}],"balance_after":4700,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4700},"source":{"system":"sec-edgar","filing":"0001171843-20-001362","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320001362/ownership.xml","form_type":"4"}},{"id":3465453,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-09T20:10:15.000Z","date":"2019-07-08","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in three equal annual installments beginning July 8, 2020."}],"balance_after":27000,"derivative":{"exercise_price":40.67,"expiration_date":"2029-07-08","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001171843-19-004474","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184319004474/ownership.xml","form_type":"4"}},{"id":3465452,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Business Development"}}],"security":"Restricted Stock Unit","published_at":"2019-07-09T20:10:15.000Z","date":"2019-07-08","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020."}],"balance_after":9000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001171843-19-004474","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184319004474/ownership.xml","form_type":"4"}}]}